Novel methods of analyzing radio-frequency echo signals for the purpose of imaging brachytherapy seeds used to treat prostate cancer

Brachytherapy using small implanted radioactive seeds is becoming an increasingly popular method for treating prostate cancer. Seeds are inserted into the prostate transperineally using ultrasound guidance. Dosimetry software determines the optimal placement of seeds for achieving the prescribed dose based on ultrasonic determination of the gland boundaries. However, because of prostate movement after planning images are acquired and during the implantation procedure, seeds commonly are not placed in the desired locations and the delivered dose may differ from the prescribed dose. Current methods of ultrasonic imaging do not adequately display implanted seeds for the purpose of correcting the delivered dose. We are investigating new methods of ultrasonic imaging that overcome limitations of conventional ultrasound. These methods include resonance, modified elastographic, and signature techniques. Each method shows promise for enhancing the visibility of seeds in ultrasound images. Combining the information provided by each method may reduce ambiguities in determining where seeds are present or absent. If successful, these novel imaging methods will enable correction of seed-misplacement errors during the implantation procedure, and hence will improve the therapeutic radiation dose delivered to target tissues.

[1]  J Roy,et al.  Short-term morbidity from CT-planned transperineal I-125 prostate implants. , 1993, International journal of radiation oncology, biology, physics.

[2]  P. Roberson,et al.  Source placement error for permanent implant of the prostate. , 1997, Medical physics.

[3]  J J Prete,et al.  Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. , 1998, International journal of radiation oncology, biology, physics.

[4]  J Roy,et al.  Treatment-related symptoms during the first year following transperineal 125I prostate implantation. , 1994, International journal of radiation oncology, biology, physics.

[5]  N. Yue,et al.  Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition. , 1998, International journal of radiation oncology, biology, physics.

[6]  S Nag,et al.  Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration. , 1995, Urology.

[7]  P L Roberson,et al.  Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants. , 1997, International journal of radiation oncology, biology, physics.

[8]  C. Clifton Ling,et al.  Determining source strength and source distribution for a transperineal prostate implant , 1996 .

[9]  F M Waterman,et al.  Limitations of the minimum peripheral dose as a parameter for dose specification in permanent 125I prostate implants. , 1996, International journal of radiation oncology, biology, physics.

[10]  H. Hricak,et al.  Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. , 1996, International journal of radiation oncology, biology, physics.

[11]  M Zaider,et al.  Dosimetric and volumetric criteria for selecting a source activity and a source type ((125)I or (103)Pd) in the presence of irregular seed placement in permanent prostate implants. , 2000, International journal of radiation oncology, biology, physics.